Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children11110.24287/1726-1708-2015-14-3-48-54ACUTE LEUKEMIAОСТРЫЙ ЛЕЙКОЗDiagnosis and treatment of acute myeloid leukemia in children: Modern aspectsСовременные аспекты диагностики и лечения острого миелоидного лейкоза у детейBarovskayaYu. A.БаровскаяЮ. А.
Russian Federation
ju1ia@tut.byRepublican Center of Pediatric Oncology, Hematology, and ImmunologyРеспубликанский научно-практический центр детской онкологии, гематологии и иммунологии Минздрава Республики Беларусь19092015143485419092018Copyright ©; 2015, «D. Rogachev NMRCPHOI»Copyright ©; 2015, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2015«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/111

Acute myeloid leukemia (AML) in children is presented by an extremely heterogeneous group of diseases; for this reason, optimization of methods for its therapy is a difficult task. This review of literature presents modern concepts of the prognostic factors, based on the genetic changes in tumor cells, and the modern potentialities of therapy for AML.

Острый миелоидный лейкоз (ОМЛ) у детей представлен крайне гетерогенной группой заболеваний, в связи с этим оптимизация методов лечения данной патологии является трудной задачей. В статье, представляющей собой обзор литературы, описаны современные представления о факторах прогноза, основанных на генетических изменениях в опухолевых клетках, а также существующие на сегодняшний день возможности терапии ОМЛ.

детиострый миелоидный лейкоздиагностикагенетические аномалиифакторы прогнозалечениеиммунотерапияchildrenacute myeloid leukemiadiagnosisgenetic abnormalitiesprognostic factorstherapyimmunotherapyПетрович СВ, Алейникова ОВ, Шумихина ТП, Чуниховский СП, Федорова ЛЮ, Сахарова ОГидр. Эпидемиологические аспекты онкогематологических забо- леваний у детей в Республике Беларусь. Вопросы онкологии. 2002;48(3): 301-5Faulk K, Gore L, Сooper T. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia. Pediatr Drugs. 2014; 16(3):213-27Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K, et al. Result of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. Br J Haematol. 2011;155(3):366-76Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543-52Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122(2):170-8Сooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer. 2012;118(3):761-9Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, Jónsson OG, Lausen B, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2013;29(3):310-5Creutzig U, Zimmermann M, Bourquin J, Dworzak MN, Fleischhack G, Graf N, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013;122(1):37-43Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002;39(4, Suppl. 3):6-11Гук ЛГ. Анализ мутаций в генах FLT3, KIT, MLL, NPM1 у детей с острым мие- лоидным лейкозом. Автореф. дисс. … канд. мед. наук. М., 2010Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 2011;4:36Rubnitz JE, Inaba Н. Childhood acute myeloid leukemia. Br J Haematol. 2012;159(3):259-76Pui CH, Carroll W, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-65Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187-205El Rassi F, Arellano M. Update on optimal management of acute myeloid leukemia. Clin Med Insights Oncol. 2013;7:181-97Paschka P, Döhner K. Сore-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Hematology Am Soc Hematol Educ Program. 2013;2013:209-19Rubnitz JE. How I treat pediatric acute myeloid leukemia. Blood. 2012;119(25): 5980-8Сairoli R, Beghini A, Grillo G. Nadali G, Elice F, Ripamonti CB, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463-8Boissel N, Leroy H, Brethon B, Philippe N, de Botton S, Auvrignon A, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965-70Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115(12):2372-9Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ, et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica. 2011; 96(3):384-92Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-86Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2009;113(26):6558-66Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12. J Clin Oncol. 2010;28(16): 2674-81Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593-603Liang DC, Liu HC, Yang СP, Jaing TH, Hung IJ, Yeh TC, et al. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on muta- tions of ASXL1, TET2, IDH1, IDH2, and DNMT3. Blood. 2013;121(15):2988-95Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi VV, et al. Combi- nation of cladribine and cytarabine is effective for childhood acute myeloid leukemia: result of the St Jude AML97 trial. Leukemia. 2009;23(8):1410-6Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, et al. Outcomes in CCG-2961, a Сhildren’s Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Blood. 2008;111(3):1044-53Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001; 15(3):348-54Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586-95Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155(3):366-76Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, Graf N, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013;122(1):37-43Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56-62Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. The value of allogeneic bone marrow transplant in patient with acute myeloid leukaemia at different risk of relapse: result of the UK MRC AML 10 trial. Br J Haematol. 2002;118(2):385-400Neiwerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116(13):2205-14Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955-9Meleshko AN, Savva NN, Fedasenka UU, Romancova AS, Krasko OV, Eckert C, et al. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols. Leuk Res. 2011;35(10):1312-20Sievers EL, Lange BG, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003;101(9):3398-406Сampana D, Coustan-Smith E. Measurements of treatment response in childhood acute leukemia. Korean J Hematol. 2012;47(4):245-54Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, et al. Clinical implication of FLT3 mutations in pediatric AML. Blood. 2006;108(12): 3654-61Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, et al. Mutant FLT3 a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100(3):184-98Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984-92Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010;28(11): 1856-62Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2001;117(2):3294-301Levis M, Pham R, Smith BD, Small D. In vivo studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104(4):1145-50Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol. 2011;29(24):3293-300Демидова ИА. Эпигенетические нарушения при острых лейкозах. Клиническая онкогематология. 2008;1(1):16-20Garcia-Manero G, Kantarijian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108(10):3271-9Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patient with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012;30(18):2204-10Попа АВ, Горохова ЕВ, Серебрякова ИН, Фечина ЛГ, Хлебникова ОП, Тупицын ННидр. Эпигенетическая терапия индукции ремиссии у детей, больных острым миелоидным лейкозом. Клиническая онкогематология. 2008;1(1):34-8Moretta A, Bottino С, Mingari MС, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol. 2002;3(1):6-8Miller JS. Therapeutic application: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program. 2013;2013:247-53Babor F, Fischer JC, Uhrberg M. The role of KIR genes and ligands in leukemia surveillance. Front Immunol. 2013;4:27Cоколова ЮВ, Бубнова ЛН, Бессмельцев СС. Строение и функции иммуно- глобулинподобных рецепторов киллерных клеток в норме и патологии. Medline.ru - Биомедицинский журнал. 2010;11(2):635-57Ljunggren HG, Kärre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237-44Hallett WH, Murphy WJ. Natural killer cells: biology and clinical use in cancer therapy. Cell Mol Immunol. 2004;1(1):12-21Beelen DW, Ottinger HD, Ferencik S, Elmaagacli AH, Peceny R, Trenschel R, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005; 105(6):2594-600Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110(1):433-40Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-7